Skip to main content
Top
Published in: International Journal of Clinical Oncology 5/2019

01-05-2019 | Acute Myeloid Leukemia | Original Article

c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia

Authors: Hiroyuki Kubo, Osamu Imataki, Yukiko Hamasaki Kubo, Makiko Uemura, Norimitsu Kadowaki

Published in: International Journal of Clinical Oncology | Issue 5/2019

Login to get access

Abstract

Background

D-index is a recently established clinical tool for assessing neutropenia severity. This study examined whether the D-index can predict the onset of various infections in patients with febrile neutropenia (FN).

Methods

We retrospectively investigated FN events in consecutive patients aged < 65 years who were treated for newly diagnosed acute myeloid leukemia at our institution. We collected data on all FN events during chemotherapy and evaluated the association of FN severity with infectious events. Results: This study included 35 patients (18 women and 17 men; median age, 51 years [range 18–65 years]) with 122 FN events. The response rate to induction chemotherapy was 60% (21/35), and all but one patient survived the treatment. The D-index did not predict FN onset. However, in multivariate analysis, high-dose cytarabine and total D-index were statistically significant explanatory factors for microbiological-proven infections. In addition, multivariate analysis showed that diabetes mellitus is the only risk factor for FN onset. Furthermore, older age, consolidation therapy, and cumulative D-index (c-D-index) were risk factors for prolonged FN. The FN period was the longest in patients with respiratory infections.

Conclusion

The D-index did not predict the onset of infection. However, FN duration might be prolonged during consolidation therapy in elderly patients with diabetes mellitus, and it is important to manage respiratory infections. These findings indicate the c-D-index is a useful tool to predict prolonged FN.
Literature
1.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA et al. (2011) Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431CrossRef Freifeld AG, Bow EJ, Sepkowitz KA et al. (2011) Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431CrossRef
2.
go back to reference Portugal RD, Garnica M, Nucci M (2009) Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 27:3849–3854CrossRef Portugal RD, Garnica M, Nucci M (2009) Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 27:3849–3854CrossRef
3.
go back to reference Kimura S, Oshima K, Sato K et al. (2010) Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transpl 16:1355–1361CrossRef Kimura S, Oshima K, Sato K et al. (2010) Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transpl 16:1355–1361CrossRef
4.
go back to reference Kimura S, Wada H, Ishihara Y et al. (2014) D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. Hematology 19:107–112CrossRef Kimura S, Wada H, Ishihara Y et al. (2014) D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. Hematology 19:107–112CrossRef
5.
go back to reference Aoki J, Tsubokura M, Kakihana K et al. (2014) The predictive value for pulmonary infection by area over the neutrophil curve (D-index) in patients who underwent reduced intensity hematopoietic stem cell transplantation. Pathol Oncol Res 20:879–883CrossRef Aoki J, Tsubokura M, Kakihana K et al. (2014) The predictive value for pulmonary infection by area over the neutrophil curve (D-index) in patients who underwent reduced intensity hematopoietic stem cell transplantation. Pathol Oncol Res 20:879–883CrossRef
6.
go back to reference Ishihara Y, Kimura S, Akahoshi Y et al. (2016) Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma. Hematology 21:19–25CrossRef Ishihara Y, Kimura S, Akahoshi Y et al. (2016) Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma. Hematology 21:19–25CrossRef
7.
go back to reference Sakamaki H, Miyawaki S, Ohtake S et al. (2010) Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. Int J Hematol 91:284–292CrossRef Sakamaki H, Miyawaki S, Ohtake S et al. (2010) Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. Int J Hematol 91:284–292CrossRef
8.
go back to reference Ohtake S, Miyawaki S, Fujita H et al. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117:2358–2365CrossRef Ohtake S, Miyawaki S, Fujita H et al. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117:2358–2365CrossRef
9.
go back to reference Radfar M, Faghihi T, Hadjibabaie M et al. (2015) Impact of preexisting diabetes mellitus on transplantation outcomes in hematopoietic stem cell transplantation. Endocr Res 40:20–24CrossRef Radfar M, Faghihi T, Hadjibabaie M et al. (2015) Impact of preexisting diabetes mellitus on transplantation outcomes in hematopoietic stem cell transplantation. Endocr Res 40:20–24CrossRef
10.
go back to reference Lynn JJ, Chen KF, Weng YM et al. (2013) Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol 31:189–196CrossRef Lynn JJ, Chen KF, Weng YM et al. (2013) Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol 31:189–196CrossRef
11.
go back to reference Takenaka Y, Cho H, Yamamoto M et al. (2013) Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Support Care Cancer 21:2861–2868CrossRef Takenaka Y, Cho H, Yamamoto M et al. (2013) Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Support Care Cancer 21:2861–2868CrossRef
12.
go back to reference Bellesso M, Costa SF, Pracchia LF et al. (2011) Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies. Ann Hematol 90:455–462CrossRef Bellesso M, Costa SF, Pracchia LF et al. (2011) Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies. Ann Hematol 90:455–462CrossRef
13.
go back to reference de Naurois J, Novitzky-Basso I, Gill MJ et al. ESMO Guidelines Working Group (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5):v252–6CrossRef de Naurois J, Novitzky-Basso I, Gill MJ et al. ESMO Guidelines Working Group (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5):v252–6CrossRef
14.
go back to reference Schaich M, Parmentier S, Kramer M et al. (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol 31:2094–2102CrossRef Schaich M, Parmentier S, Kramer M et al. (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol 31:2094–2102CrossRef
15.
go back to reference Wang L, Hu J, Sun Y et al. (2016) Does high-dose cytarabine cause more fungal infection in patients with acute myeloid leukemia undergoing consolidation therapy: a Multicenter, Prospective, Observational Study in China. Medicine (Baltimore) 95:e2560CrossRef Wang L, Hu J, Sun Y et al. (2016) Does high-dose cytarabine cause more fungal infection in patients with acute myeloid leukemia undergoing consolidation therapy: a Multicenter, Prospective, Observational Study in China. Medicine (Baltimore) 95:e2560CrossRef
16.
go back to reference Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S32–S37CrossRef Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S32–S37CrossRef
Metadata
Title
c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia
Authors
Hiroyuki Kubo
Osamu Imataki
Yukiko Hamasaki Kubo
Makiko Uemura
Norimitsu Kadowaki
Publication date
01-05-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 5/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-01384-9

Other articles of this Issue 5/2019

International Journal of Clinical Oncology 5/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine